ESC Premium Access

Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.


About the speaker

Doctor Hidekazu Kondo

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)
0 follower

6 more presentations in this session

Circulating microparticules of patients with coronary artery disease up-regulate the expression of sodium-glucose cotransporters 1 and 2 in coronary artery endothelial cells: role of angiotensin II

Speaker: Doctor S. Park (Illkirch, FR)


Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials

Speaker: Mr C. Parco (Duesseldorf, DE)


Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

Speaker: Mr J. Ghouse (Copenhagen, DK)


Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Speaker: Professor D. McGuire (Dallas, US)


The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis

Speaker: Professor C. Desouza (Omaha, US)


Access the full session

Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

Speakers: Doctor H. Kondo, Doctor S. Park, Mr C. Parco, Mr J. Ghouse, Professor D. McGuire...

About the event



31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk